- Home
- VMD vs VOR Comparison
VMD vs VOR Comparison
Compare VMD & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- VOR
- Stock Information
- Founded
- VMD 2006
- VOR 2015
- Country
- VMD United States
- VOR United States
- Employees
- VMD N/A
- VOR N/A
- Industry
- VMD
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- VOR Health Care
- Exchange
- VMD Nasdaq
- VOR Nasdaq
- Market Cap
- VMD 280.4M
- VOR 261.0M
- IPO Year
- VMD N/A
- VOR 2021
- Fundamental
- Price
- VMD $6.87
- VOR $33.79
- Analyst Decision
- VMD
- VOR Buy
- Analyst Count
- VMD 0
- VOR 6
- Target Price
- VMD N/A
- VOR $78.00
- AVG Volume (30 Days)
- VMD 177.7K
- VOR 455.3K
- Earning Date
- VMD 11-05-2025
- VOR 11-06-2025
- Dividend Yield
- VMD N/A
- VOR N/A
- EPS Growth
- VMD 47.14
- VOR N/A
- EPS
- VMD 0.34
- VOR N/A
- Revenue
- VMD $240,884,000.00
- VOR N/A
- Revenue This Year
- VMD $19.22
- VOR N/A
- Revenue Next Year
- VMD $17.51
- VOR N/A
- P/E Ratio
- VMD $20.41
- VOR N/A
- Revenue Growth
- VMD 17.11
- VOR N/A
- 52 Week Low
- VMD $5.93
- VOR $2.62
- 52 Week High
- VMD $9.81
- VOR $65.80
- Technical
- Relative Strength Index (RSI)
- VMD 51.33
- VOR 61.12
- Support Level
- VMD $6.71
- VOR $36.67
- Resistance Level
- VMD $7.04
- VOR $49.95
- Average True Range (ATR)
- VMD 0.20
- VOR 4.63
- MACD
- VMD 0.01
- VOR -0.51
- Stochastic Oscillator
- VMD 67.92
- VOR 34.22
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.